18F-fluoro-ethyl-tyrosine PET co-registered with MRI in patients with persisting acromegaly Article Swipe

PDF

Related Concepts

Medicine Acromegaly Positron emission tomography Magnetic resonance imaging Radiology Debulking Nuclear medicine Internal medicine Cancer Growth hormone Ovarian cancer Hormone

Leontine E. H. Bakker , Marco J. T. Verstegen , Diandra C. Manole , Huangling Lu , Thomas Decramer , Iris C. M. Pelsma , Mark C. Kruit , Berit M. Verbist , Annenienke van de Ven , Mark Gurnell , Idris Ghariq , Wouter R. van Furth , Nienke R. Biermasz , Lenka M. Pereira Arias‐Bouda ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.21203/rs.3.rs-3799944/v1 · OA: W4390496590

<title>Abstract</title> Purpose To report our experience with 18F-fluoro-ethyl-tyrosine (FET) positron emission tomography-computed tomography (PET-CT) co-registered with MRI (FET-PET/MRICR) in the care trajectory for complex acromegaly patients. Methods In 10 patients with insufficiently controlled acromegaly referred to our team to evaluate surgical options, FET-PET/MRICR was used to support decision-making if MRI alone and multidisciplinary team evaluation did not provide sufficient clarity to proceed to surgery. Results FET-PET/MRICR showed suspicious (para)sellar tracer uptake in all patients. In 5 patients FET-PET/MRICR was fully concordant with conventional MRI, and in 1 patient partially concordant. FET-PET/MRICR identified new suspicious foci in 4 other patients. Surgical re-exploration was performed in 9 patients (aimed at total resection (6), debulking (2), diagnosis (1)), and 1 patient underwent radiation therapy. In 7 of 9 (78%) operated patients FET-PET/MRICR findings were confirmed intraoperatively, and in 6 patients (67%) also histologically. IGF-1 decreased significantly in 8 patients (89%). All patients showed clinical improvement. Complete biochemical remission was achieved in 3 patients (50% of procedures in which total resection was anticipated feasible). Biochemistry improved in 5 and was unchanged in 1 patient. No permanent complications occurred. Outcome categorized by integrated outcome quadrants (IOQs) defined by preoperative intended effect versus permanent complications at 6 months was IOQ-1 (goal achieved without complications) in 6 (67%) and IOQ-3 (goal not achieved, no complications) in 3 patients. Conclusion In complex acromegaly cases FET-PET/MRICR can provide additional information to aid decision-making by the multidisciplinary pituitary team, especially when (further) surgery is being considered.